CLEVELAND, June 8 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced their exhibition at the 45th DIA Annual Meeting to be held later this month in San Diego, California. DATATRAK will be unveiling new branding as well as a number of exciting new features and functionality in their DATATRAK eClinical(TM) solution including:
“Attendance at the DIA show is always a great opportunity to renew relationships,” said DATATRAK President and CEO, Laurence Birch. “With each release of the DATATRAK eClinical(TM) product, we enhance and streamline the user experience, creating efficiencies for our clients. We look forward to demonstrating these capabilities to industry leaders in San Diego.”
The DATATRAK team will be providing product demonstrations and additional information at the DATATRAK booth (#1525). If you would like to schedule a personal demonstration during the show, please email marketing@datatrak.net to set up an appointment.
About 45th Annual DIA Meeting.
The DIA Annual Meeting is the biopharmaceutical industry’s largest global, multidisciplinary event. The 45th DIA Annual Meeting’s focus is ‘Better Medicines: Improving Safety with Every Step’ and is being held June 21-25, 2009 at the San Diego Convention Center in San Diego, California. For the first time ever, DIA is offering LIVE online content from the Annual Meeting. For more information on the meeting, visit http://www.diahome.org.
About DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK’s eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company’s performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company’s quarterly results; the viability of the Company’s business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company’s dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other’s intellectual property rights; the Company’s success in integrating its acquisition’s operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company’s success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
CONTACT: Raymond J. Merk, Chief Financial Officer and Chief Operating
Officer, DATATRAK International, Inc., +1-440-443-0082 x181
Web site: http://www.datatrak.net/
